Physician
Dynamic Pain & Wellness PLLC
Dynamic Pain & Wellness PLLC was paid $10.89M by Medicaid between Jan 2018 and Dec 2024, across 81 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 36% of everything it billed.
33Billing provider infoDYNAMIC PAIN & WELLNESS PLLC
FORT WALTON BEACH, FL 32547
FORT WALTON BEACH, FL 32547
33aNPI1285007989assigned 11/04/2015
33bProvider typeAnesthesiology Physician
28Total paid$10.89M
24GClaims580,514
24DCodes billed81
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Florida
Rank by total paid#1 of 148
Median peer was paid$20K
This provider vs. median544×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,055 | $26K | |
| 2019 | 124,277 | $1.47M | |
| 2020 | 97,507 | $2.08M | |
| 2021 | 80,052 | $1.92M | |
| 2022 | 101,224 | $1.90M | |
| 2023 | 85,658 | $2.17M | |
| 2024incomplete | 50,741 | $1.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 36% | 154,744 | 123,596 | $3.88M |
| 64493 | 12% | 13,239 | 8,460 | $1.28M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.6% | 36,973 | 27,862 | $938K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 7.4% | 15,767 | 10,615 | $809K |
| 64635 | 6.7% | 4,305 | 3,445 | $731K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.3% | 7,467 | 6,166 | $472K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.3% | 22,642 | 18,815 | $361K |
| 20610 | 3.2% | 13,761 | 10,158 | $352K | |
| 27096 | 3.1% | 4,293 | 3,049 | $339K | |
| 64494 | 3.1% | 14,505 | 8,167 | $336K | |
| 20553 | 2.2% | 10,178 | 8,478 | $244K | |
| 77002 | 2.2% | 13,433 | 10,130 | $243K |
69 more codes
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.2% | 4,559 | $235K |
| 64636 | 1.5% | 4,137 | $163K | |
| 64490 | <1% | 728 | $103K | |
| 80305 | <1% | 15,172 | $91K | |
| 99454 | <1% | 16,018 | $55K | |
| 64495 | <1% | 5,130 | $50K | |
| 62323 | <1% | 240 | $27K | |
| 64491 | <1% | 722 | $20K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 46,126 | $18K |
| 99457 | <1% | 15,163 | $18K | |
| 64633 | <1% | 85 | $16K | |
| 64492 | <1% | 289 | $15K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 328 | $15K |
| 99458 | <1% | 8,424 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,846 | $10K |
| 64634 | <1% | 100 | $6K | |
| 99205 | Prolong outpt/office vis | <1% | 99 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 381 | $4K |
| 96138 | <1% | 16,541 | $3K | |
| 80373 | <1% | 324 | $2K | |
| 80357 | <1% | 324 | $2K | |
| 80368 | <1% | 323 | $2K | |
| 80370 | <1% | 322 | $2K | |
| 80347 | <1% | 302 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 40 | $2K |
| 20611 | <1% | 127 | $2K | |
| 80365 | <1% | 301 | $2K | |
| 80356 | <1% | 301 | $2K | |
| 80348 | <1% | 302 | $2K | |
| 80354 | <1% | 302 | $2K | |
| 80364 | <1% | 302 | $2K | |
| 80349 | <1% | 302 | $2K | |
| 80371 | <1% | 302 | $2K | |
| 80358 | <1% | 302 | $2K | |
| 80352 | <1% | 302 | $2K | |
| 80360 | <1% | 303 | $2K | |
| 80331 | <1% | 322 | $2K | |
| 80353 | <1% | 302 | $2K | |
| 80359 | <1% | 302 | $2K | |
| 80326 | <1% | 301 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,028 | $1K |
| 80322 | <1% | 299 | $1K | |
| 80345 | <1% | 301 | $1K | |
| 99453 | <1% | 273 | $750.12 | |
| 20552 | <1% | 19 | $431.36 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $387.43 |
| L0637 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 122 | $271.80 |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 80 | $271.80 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 14 | $77.96 |
| 97750 | <1% | 147 | $46.48 | |
| 99051 | <1% | 90 | $36.40 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 5,141 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 4,473 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 10,208 | $0.00 |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 8,811 | $0.00 |
| L1833 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the shelf | 0% | 48 | $0.00 |
| L0180 | Cervical, multiple post collar, occipital/mandibular supports, adjustable | 0% | 12 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 8,807 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 10,724 | $0.00 |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | 0% | 5,266 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 5,751 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 10,708 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 8,813 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 10,091 | $0.00 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 10,089 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 8,809 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 8,817 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 4,850 | $0.00 |
| 80355 | 0% | 306 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCUNE, MATHEW (CEO)